Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cedars-Sinai Medical Center
The primary objective of the study is to determine the locoregional recurrence rate in patients with clinically node negative T1 and T2 breast cancer treated with systemic chemotherapy and whole breast irradiation in whom biopsy of the sentinel node is not performed. A locoregional recurrence is defined as any recurrence in the ipsilateral axillary nodes or in the supraclavicular nodes.
After surgery, a patient will receive standard of care radiation on her affected breast and chemotherapy. A physical examination of the affected breast and regional lymph nodes will be conducted every six months for the first two years of follow up and then yearly for the last 3 years of follow up. Imaging of the affected breast will occur every 12 months after surgery per standard of care.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female age 18 and older, not pregnant or lactating
Clinical T1 or T2 invasive cancer with no suspicious palpable adenopathy
If abnormal axillary nodes are seen on preoperative imaging, a negative fine needle aspiration or core biopsy is required for study entry.
Planned treatment with breast conserving surgery and whole breast irradiation
Chemotherapy required postoperatively based on patient and tumor characteristics at diagnosis
You may not be if
Patients with suspicious palpable axillary adenopathy
Patients with biopsy demonstrating axillary nodal metastases
Patients with treatment by mastectomy
Patients who have undergone neoadjuvant chemotherapy
Patients with co-morbidities rendering the patient not a candidate for chemotherapy, surgery, or irradiation
Patients treated with accelerated partial breast irradiation (APBI)
Patients with contraindication to radiation
Clareo Health | Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy
